The Korean journal of internal medicine

  • 제39권5호
  • /
  • Pages.759-769
  • /
  • 2024
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Primary surgery versus pharmacotherapy for newly diagnosed ileocecal Crohn's disease: a hospital-based cohort study

  • Yehyun Park (Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine) ;
  • Soo Jung Park (Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine) ;
  • Tae Il Kim (Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine) ;
  • Won Ho Kim (Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine) ;
  • Jae Hee Cheon (Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine)
  • 투고 : 2023.12.06
  • 심사 : 2024.03.28
  • 발행 : 2024.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Limited knowledge exists regarding the optimal timing and relative advantages of primary surgery compared to medical treatment in ileocecal Crohn's disease (CD). This study aimed to compare long-term outcomes between medication-based treatment versus surgery in newly diagnosed ileocecal CD patients in an Asian population. Methods: Among the 885 patients diagnosed with CD and enrolled in the study site hospital cohort between 1980 and 2013, 93 (10.5%) had ileocecal CD. Patients were categorized into either the surgical or medical remission group based on their initial management strategy that led to remission. The rates of relapse, hospitalization, and surgery after achieving remission were compared using Kaplan-Meier curves. Results: The numbers of patients assigned to surgical and medical remission groups were 15 (17.0%) and 73 (83.0%), respectively. The surgical remission group exhibited a lower relapse rate and longer maintenance of remission (10.7 vs. 3.7 yr; p = 0.017) during a median follow-up of 6.6 years. Hospitalization after the first remission tended to be lower in the surgical remission group (p = 0.054). No cases required repeated intestinal resection after the initial surgical remission, whereas a 23% surgery rate was reported at 5 years after initial medical treatment (p = 0.037). In the multivariable analysis, the initial medication-based treatment was significantly associated with relapse (hazard ratio = 3.23, p = 0.039). Conclusions: In selected cases of localized ileocecal CD, ileocolic resection might be a favorable alternative to medication-based treatment, as it demonstrates a lower relapse rate and longer maintenance of remission.

키워드

참고문헌

  1. Chow DK, Leong RW, Lai LH, et al. Changes in Crohn's disease phenotype over time in the Chinese population: validation of the Montreal classification system. Inflamm Bowel Dis 2008;14:536-541.
  2. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-250.
  3. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010;139:1147-1155.
  4. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-869.
  5. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008;135:1493-1499.
  6. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-667.
  7. Ordas I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut 2011;60:1754-1763.
  8. Hart AL, Lomer M, Verjee A, et al. What are the top 10 research questions in the treatment of inflammatory bowel disease? A priority setting partnership with the James Lind Alliance. J Crohns Colitis 2017;11:204-211.
  9. Gomollon F, Dignass A, Annese V, et al. 3rd European evidence- based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 2017;11:3-25.
  10. Freeman HJ. Application of the Montreal classification for Crohn's disease to a single clinician database of 1015 patients. Can J Gastroenterol 2007;21:363-366.
  11. Cullen G, O'toole A, Keegan D, Sheahan K, Hyland JM, O'donoghue DP. Long-term clinical results of ileocecal resection for Crohn's disease. Inflamm Bowel Dis 2007;13:1369-1373.
  12. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000;231:38-45.
  13. Bemelman WA, Allez M. The surgical intervention: earlier or never? Best Pract Res Clin Gastroenterol 2014;28:497-503.
  14. Kim NK, Senagore AJ, Luchtefeld MA, et al. Long-term outcome after ileocecal resection for Crohn's disease. Am Surg 1997;63:627-633.
  15. Rink AD, Fischer IR, Vestweber B, Vestweber KH. Long-term outcome of laparoscopic ileocecal resection for Crohn's disease before the era of biologics. Int J Colorectal Dis 2014;29:127-132.
  16. Diederen K, de Ridder L, van Rheenen P, et al. Complications and Disease recurrence after primary ileocecal resection in pediatric Crohn's disease: a multicenter cohort analysis. Inflamm Bowel Dis 2017;23:272-282.
  17. Ponsioen CY, de Groof EJ, Eshuis EJ, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol 2017;2:785-792.
  18. Stevens TW, Haasnoot ML, D'Haens GR, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial. Lancet Gastroenterol Hepatol 2020;5:900-907.
  19. Agrawal M, Ebert AC, Poulsen G, et al. Early ileocecal resection for Crohn's disease is associated with improved longterm outcomes compared with anti-tumor necrosis factor therapy: a population-based cohort study. Gastroenterology 2023;165:976-985.e3.
  20. Wright EK, Kamm MA. Impact of drug therapy and surgery on quality of life in Crohn's disease: a systematic review. Inflamm Bowel Dis 2015;21:1187-1194.
  21. Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 2: surgical management and special situations. J Crohns Colitis 2017;11:135-149.
  22. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology 2021;160:2496-2508.
  23. Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol 2020;35:380-389.
  24. Park SH. Update on the epidemiology of inflammatory bowel disease in Asia: where are we now? Intest Res 2022;20:159-164.
  25. Song EM, Yang SK. Natural history of inflammatory bowel disease: a comparison between the East and the West. Intest Res 2022;20:418-430.
  26. Cai C, Lu J, Lai L, et al. Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia. Intest Res 2022;20:213-223.
  27. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104:465- 483; quiz 464, 484.
  28. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-753.
  29. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
  30. Sampietro GM, Corsi F, Maconi G, et al. Prospective study of long-term results and prognostic factors after conservative surgery for small bowel Crohn's disease. Clin Gastroenterol Hepatol 2009;7:183-191; quiz 125.
  31. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010;105:289-297.
  32. Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R. Early versus late surgery for ileo-caecal Crohn's disease. Aliment Pharmacol Ther 2007;26:1303-1312.
  33. Lee JM, Lee KM, Kim JS, et al. Postoperative course of Crohn disease according to timing of bowel resection: Results from the CONNECT Study. Medicine (Baltimore) 2018;97:e0459.
  34. Kelm M, Anger F, Eichlinger R, et al. Early ileocecal resection is an effective therapy in isolated Crohn's disease. J Clin Med 2021;10:731.
  35. Sarikaya MZ, Zhao M, Lo B, Bendtsen F, Burisch J. Disease course and treatment outcomes of Crohn's disease patients with early or late surgery - A Danish nationwide cohort study from 1997 to 2015. Dig Liver Dis 2023;55:872-879.
  36. Gerdin L, Eriksson AS, Olaison G, et al. The Swedish Crohn trial: a prematurely terminated randomized controlled trial of thiopurines or open surgery for primary treatment of ileocaecal Crohn's disease. J Crohns Colitis 2016;10:50-54.
  37. de Groof EJ, Stevens TW, Eshuis EJ, et al. Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial. Gut. 2019;68:1774-1780.
  38. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-296.
  39. Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16:1603-1609.
  40. Nordgren SR, Fasth SB, Oresland TO, Hulten LA. Long-term follow-up in Crohn's disease. Mortality, morbidity, and functional status. Scand J Gastroenterol 1994;29:1122-1128.
  41. Weston LA, Roberts PL, Schoetz DJ Jr, Coller JA, Murray JJ, Rusin LC. Ileocolic resection for acute presentation of Crohn's disease of the ileum. Dis Colon Rectum 1996;39:841-846.
  42. Spinelli A, Carvello M, Adamina M, et al. Patients' perceptions of surgery for inflammatory bowel disease. Colorectal Dis 2021;23:2690-2698.